Is there a link between androgen deprivation therapy (ADT) for prostate cancer and dementia? That is what a cohort study of men treated with ADT sought to determine. Researchers reviewed the records of nearly 9,300 men with prostate cancer, of whom about 20% received ADT. After a mean follow-up of 3.4 years, there was a statistically significant association between use of ADT and risk of dementia (hazard ratio, 2.17; 95% confidence interval, 1.58-2.99; P < 0.001). The absolute risk of dementia was 7.9% for those who received ADT vs. 3.5% for those who did not. Men treated for at least 12 months demonstrated the greatest absolute risk of dementia. The authors suggested ADT in the treatment of prostate cancer may be associated with an increased risk of dementia. This finding should be further evaluated in prospective studies (JAMA Oncol. Published online Oct. 13, 2016. DOI:10.1001/
The authors suggested androgen deprivation therapy in the treatment of prostate cancer may be associated with an increased risk of dementia.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content